Widely used:Recently Viewed
Clear All
$17.54
$0.00 (0.00%)As on 18-Jul-2024 09:30EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-55.55 Mln
EBITDA
$-99.44 Mln
Net Profit
$-134.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Xenetic Biosciences Inc. Warrants (XBIOW)
| 338.50 | 43.18 | 135.12 | 69.63 | 116.44 | -- | -- |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
2023
|
|
|---|---|
|
Xenetic Biosciences Inc. Warrants (XBIOW)
| 100.00 |
|
BSE Sensex
| 18.74 |
|
BSE Sensex
| 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including... immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Read more
CEO, President & Director
Mr. Jeffrey F. Eisenberg Esq.
CEO, President & Director
Mr. Jeffrey F. Eisenberg Esq.
Headquarters
Framingham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Xenetic Biosciences Inc Warrants (XBIOW) is $17.54 (NASDAQ) as of 18-Jul-2024 09:30 EDT. Xenetic Biosciences Inc Warrants (XBIOW) has given a return of 116.44% in the last 3 years.
Xenetic Biosciences Inc Warrants (XBIOW) has a market capitalisation of -- as on 29-Jul-2024. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Xenetic Biosciences Inc Warrants (XBIOW) and enter the required number of quantities and click on buy to purchase the shares of Xenetic Biosciences Inc Warrants (XBIOW).
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
The CEO & director of Mr. Jeffrey F. Eisenberg Esq.. is Xenetic Biosciences Inc Warrants (XBIOW), and CFO & Sr. VP is Mr. Jeffrey F. Eisenberg Esq..
There is no promoter pledging in Xenetic Biosciences Inc Warrants (XBIOW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Xenetic Biosciences Inc. Warrants (XBIOW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Xenetic Biosciences Inc Warrants (XBIOW) was $0 Mln.
